EWA
LUCD icon

EverSource Wealth Advisors’s Lucid Diagnostics LUCD Stock Holding History

EverSource Wealth Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$459 Buy
+399
New +$508 ﹤0.01% 4082

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

EverSource Wealth Advisors's LUCD Position: Q1 2026 in Review

EverSource Wealth Advisors opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 399 shares worth $459. The stake represents ﹤0.01% of the portfolio and ranks #4082 among its holdings.

103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • EverSource Wealth Advisors held 399 shares of Lucid Diagnostics worth $459 as of Q1 2026.
  • Lucid Diagnostics was a new EverSource Wealth Advisors position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4082 holding.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.